Unlike any other market in the U.S., the D.C. market for medical cannabis must contend with federal funding and regulation interferences. AGG partner Kevin M. Bell discusses the tension between district and federal lawmakers with Benzinga.
To read the full article, please click here.
Related Industries
Primary Contacts
- Kevin M. Bell
Partner